CO5080801A1 - Inhibidores de proteasas - Google Patents

Inhibidores de proteasas

Info

Publication number
CO5080801A1
CO5080801A1 CO99030929A CO99030929A CO5080801A1 CO 5080801 A1 CO5080801 A1 CO 5080801A1 CO 99030929 A CO99030929 A CO 99030929A CO 99030929 A CO99030929 A CO 99030929A CO 5080801 A1 CO5080801 A1 CO 5080801A1
Authority
CO
Colombia
Prior art keywords
alkyl
phenyl
substituted
group
thiophene
Prior art date
Application number
CO99030929A
Other languages
English (en)
Inventor
William Edward Bondinell
Dennis Shinji Yamashita
Renee Louise Desjarlais
Daniel Frank Veber
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5080801A1 publication Critical patent/CO5080801A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un compuesto de fórmula I:<EMI FILE="99030929_1" ID="1" IMF=JPEG >R1 y R2 son independientemente H o alquilo C1-C6, siempre y cuando R1 y R2 no sean ambos alquilo C1-C6;P es<EMI FILE="99030929_2" ID="2" IMF=JPEG >R3 se elige entre el grupo formado por CH2CH(CH3)2, CH2CH2CH3, CH2CH=CH2 ó CH2Ph;R4 se elige entre el grupo formado por:alquilo C0-C6;N-piperizina;N-tetrahidroisoquinoleína;alquilo C0-C6; sustituido con fenilo, tiofeno, benzotiazol, 2-, 3-, 4-, 5-, 6- ó 7-quinoleína, naftilo, 1-(7-nitro-2,1,3-benzoxadiazol-4-il)-L-prolilo, alquil (C0-C6)pirazol, N-Cbz-2-(N,N-dimetilamino)etilglicil-, N-metilpirrol, benzoxazol, benciloxi, alcoxi C1-C6; 2, 3, ó 4-piridiniloxi; adamantilo, tieno[3, 2-b]tiofeno;fenilo; tiofeno; benzotiofeno; benzofurano, benzotiazol; 2-, 3-, 4-, 5-, 6- ó 7-quinoleína; naftilo y benzoxazol, cada uno de ellos independientemente sustituido con uno o más de los grupos alquilo C1-C6, halógeno nitro, ciano, hidroxi, alcoxi C1-C6, trifluorometilo, carboxilo, éster carboxi-alquilo (C1-C6), alquil (C0-C6 )2 N-alquilo C0 -C6, alquil (C0-C6 )2 N-alcoxi C0-C6, N-(C0-C6 )-N-piperizina, N-(N-alquil(C0-C6)-N-piperidina)-4-alquil(C0-C6)-amina, (alquil(C0-C6)2 N-alquil (C0-C6)-alquil (C0-C6)-amina, N-morfolino-alquilo C0-C6, N-morfolino-alcoxi C0-C6, fenilo, tiofeno, benzotiazol, 2, 3, 4, 5, 6, ó 7-quinoleína, naftilo, alquil (C0-C6)pirazol, N-metil-pirrol, benzoxazol;benciloxi sustituido con uno o más grupos alquilo (C1-C6), halógeno, nitro, ciano, hidroxi, alcoxi (C1-C6 ), trifluorometilo, carboxilo, éster carboxi alquilo (C1-C6), fenilo, tiofeno, benzotiazol, 2, 3, 4, 5, 6, ó 7 quinoleína, naftilo, alquil (C0 -C6 )pirazol, N-metil-pirrol, y benzoxazol; y pirazina;pirimidina;2,7-dimetilpirazolo [1, 5a ]pirimidina y - 2 -4,7-dimetilpirazolo [5,1-c][1,2,4]-triazina.R6 se elige entre el grupo formado por fenilo y fenilo sustituido con alquilo (C0-C6), N-piperidina, benzofurano; o 2, 3 ó 4 piridina;Q es<EMI FILE="99030929_3" ID="3" IMF=JPEG >En la que:R7 se elige entre el grupo formado por fenilo y fenilo sustituido con alquilo C0-C6), N-piperidina, benzofurano; o 2, 3 ó 4 piridina;R8 se elige entre el grupo formado por H, CH2CH(CH3)2, CH2CH2CH3 y CH2CH=CH2, CH2 Ph, cuando R9 es H; oR8 y R9 se eligen independientemente entre el grupo formado por alquilo (C1-C6); 3-(2-piridil)-fenilacetilo; 3-bifenil-acetilo; 3-(2-piridil)-fenilacetilo sustituido con 2-alquilo (C1-C6); 3-bifenil-acetilo sustituido con 2-alquilo (C1-C6); 3-(2-piridil)-fenilacetilo disustituido con 2,2-alquilo (C1-C6); 3-bifenil-acetilo disustituido con 2,2-alquilo (C1-C6), (C1-C6), fenil-sulfonilo; 2-, 3- ó 4-pirina-sulfonilo; fenilo; alquil (C0-C6)sulfonilo; alquil (C0-C6) carbonilo; yfenil-sulfonilo; fenilo; alquil (C0-C6) sulfonilo; o alquil(C0-C6)carbonilo sustituidos independientemente con uno o más grupos alquilo (C1-C6), halógeno, nitro, ciano, hidroxi, alcoxi (C1-C6), trifluorometilo, carboxilo, éster carboxialquilo (C1-C6 ), fenilo , tiofeno, benzotiazol, 2-, 3-, 4-, 5-, 6- ó 7-quinoleína, naftilo, alquil(C0-C6) pirazol, N-metil-pirrol, benzoxazol;y sus sales, hidratos y solvatos aceptables farmacéuticamente.Compuestos según la reivindicación 1 administrables a pacientes para inhibir proteasas del grupo formado por proteasa de cicteína y de serina.1Compuestos conforme a la reivindicación o punto 1 administrables en pacientes afectados por degradación excesiva de cartílago o de matriz.2Compuestos según la reivindicaciones 3 y 23 administrables contra la osteoporosis.2Compuestos según la reivindicación 3 y 23 administrables contra la artritis rumatoide.
CO99030929A 1998-05-21 1999-05-20 Inhibidores de proteasas CO5080801A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8655798P 1998-05-21 1998-05-21

Publications (1)

Publication Number Publication Date
CO5080801A1 true CO5080801A1 (es) 2001-09-25

Family

ID=22199378

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99030929A CO5080801A1 (es) 1998-05-21 1999-05-20 Inhibidores de proteasas

Country Status (10)

Country Link
US (1) US6518267B1 (es)
EP (1) EP1067894A4 (es)
JP (1) JP2002515411A (es)
AR (1) AR018370A1 (es)
AU (1) AU4092799A (es)
CA (1) CA2332531A1 (es)
CO (1) CO5080801A1 (es)
DZ (1) DZ2796A1 (es)
MA (1) MA26631A1 (es)
WO (1) WO1999059526A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6596715B1 (en) 1999-11-10 2003-07-22 Smithkline Beecham Corporation Protease inhibitors
AU1474801A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US7071184B2 (en) 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
FR2832405B1 (fr) * 2001-11-19 2004-12-10 Sanofi Synthelabo Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
US7282512B2 (en) 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
KR20040097375A (ko) * 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
CA2535366A1 (en) * 2003-08-27 2005-03-10 Merck Frosst Canada & Co. Cathepsin inhibitors
UY29101A1 (es) * 2004-09-07 2006-03-31 Smithkline Beecham Corp 1,3-diaminas aceclicas y usos de las mismas
WO2009128521A1 (ja) * 2008-04-15 2009-10-22 帝人ファーマ株式会社 システインプロテアーゼ阻害剤
CN104311408B (zh) * 2014-09-12 2019-11-08 沈阳化工研究院有限公司 4,4’-二苯醚二甲酸的制备方法
CN111943818B (zh) * 2020-09-16 2023-01-24 天津均凯农业科技有限公司 一种制备4,4′-双三氟甲基二苯醚的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500742A (ja) * 1995-10-30 2000-01-25 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
MA26618A1 (fr) * 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme

Also Published As

Publication number Publication date
EP1067894A2 (en) 2001-01-17
EP1067894A4 (en) 2004-09-08
AR018370A1 (es) 2001-11-14
WO1999059526A2 (en) 1999-11-25
DZ2796A1 (fr) 2003-12-01
MA26631A1 (fr) 2004-12-20
WO1999059526A3 (en) 2000-01-20
AU4092799A (en) 1999-12-06
CA2332531A1 (en) 1999-11-25
US6518267B1 (en) 2003-02-11
JP2002515411A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
CO5080801A1 (es) Inhibidores de proteasas
DK0862567T3 (da) 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister
CO5640098A2 (es) Acidos biariloximetilaren-carboxilicos
CO5300398A1 (es) Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek
TW200510353A (en) Alpha substituted carboxylic acids as PPAR modulators
CO5271675A1 (es) Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen
PE133999A1 (es) Derivados de acido hidroxamico como inhibidores de metaloproteasas de matriz (mmp)
AR009811A1 (es) Compuestos herbicidas, proceso para su produccion, proceso para la produccion de intermediarios, compuestos intermediarios para su exclusivo usoen dicho proceso, composicion que tiene actividad herbicida selectiva y proceso para el control selectivo de malas hierbas y gramineas en cultivos de planta
FI925443A0 (fi) 3-amino-2-arylkinuklidiner, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner
CO5140088A1 (es) Derivados de fenil y piridinil amida, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
DOP2010000194A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
CO4650183A1 (es) Derivados del pirrol
EA200300333A1 (ru) Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7
PE20050145A1 (es) Dihidroquinazolinas sustituidas como agentes antivirales
YU18999A (sh) Supstituisani tricikli
CO5170512A1 (es) Derivados de tetrahidroquinolin piperidina
PE20020063A1 (es) Bis-arilsulfonas como ligandos del receptor de 5-ht
DK0635015T3 (da) Acylaminoindolderivater som 5-Htl agonister
CO5261594A1 (es) Inhibidores de myt1 cinasa
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
CO5130006A1 (es) Compuestos de pirazina
PE20001234A1 (es) Compuestos azabiciclicos sustituidos de heteroaril-aminoetil/benzisoxazol como antagonistas serotonergicos 5-ht1
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
DE60218646D1 (de) N-biphenylcarbonyl- und n-phenylpyridylcarbonyl substituierte bi- and tricyclische azepine und diazepine als vasopressin-agonisten
DK0836852T3 (da) Anvendelse af amlexanox til fremstilling af et lægemiddel til behandling af aftøse sår